The candidate will be a key contributor to a scientific research team developing cutting edge methodology for testing the effectiveness of therapeutics directed against neurodegenerative protein targets. Responsibilities include development of methodology for testing effectiveness and mechanism of action of neuroprotective therapeutics expected to produce cognitive improvement. Candidate will work with internal preclinical and clinical team members, contribute to scientific publications and NIH grant applications, interface with academic collaborators and travel to scientific meetings to present company results.
What You’ll Bring
Ph.D. in In Vivo Pharmacology plus 5 years experience (industry experience a plus)
Background in neurobiology, pharmacology and biochemistry of target proteins implicated in neurodegeneration
Technical expertise in in vivo pharmacology techniques and cell culture techniques
Excellent teamwork, communication, and analytical skills
About Cognition Therapeutics
Cognition Therapeutics (CogRx) is a privately held biopharmaceutical company whose disease-relevant screening and novel chemistry platforms have produced a pipeline of disease modifying small molecule drug candidates which are being developed to treat Alzheimer’s disease and potentially other neurocognitive disorders. Cognition’s lead molecule, CT1812, is a proprietary first-in-class, orally available small molecule that is currently in clinical trials in patients with mild-to-moderate Alzheimer’s disease. This highly brain penetrant compound targets the sigma-2/PGRMC1 receptor complex, displacing toxic beta amyloid oligomers from their binding sites on brain cells and clearing them into the cerebrospinal fluid. CT1812 has been shown in multiple Alzheimer’s disease models to stop memory loss. Additional information about Cognition may be found online at http://www.cogrx.com.